Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
Clinical trial NCT05116189 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05116189
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-13
- Primary completion
- 2025-03-05
- Enrollment
- 643
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.